相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies
Esther Bettiol et al.
FUTURE MICROBIOLOGY (2014)
Global antibiotic consumption 2000 to 2010: an analysis of Cross Mark 742 national pharmaceutical sales data
Thomas P. Van Boeckel et al.
LANCET INFECTIOUS DISEASES (2014)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts et al.
LANCET INFECTIOUS DISEASES (2014)
Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010
Stephen P. Hawser et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Pharmacokinetics of ertapenem in burns patients
E. Dailly et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
Dolores Sousa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model
Thomas Tangden et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Carbapenem Therapy for Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli or Klebsiella pneumoniae: Implications of Ertapenem Susceptibility
Nan-Yao Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Vicki L. Collins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions
L. S. Tzouvelekis et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010
Chi-Chang Huang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence
David P. Nicolau et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis
Un-In Wu et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2012)
Classification and regression trees
N. Speybroeck
INTERNATIONAL JOURNAL OF PUBLIC HEALTH (2012)
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis
Konstantinos Z. Vardakas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae
Nan-Yao Lee et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy
Alexandre P. Zavascki et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations
Olaf Burkhardt et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Clinical significance of extended-spectrum beta-lactamases
Jesus Rodriguez-Bano et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2008)
Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern
Johann D. D. Pitout et al.
LANCET INFECTIOUS DISEASES (2008)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
LANCET (2007)
Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil
Carlos R. V. Kiffer et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Extended-spectrum β-lactamases:: a clinical update
DL Paterson et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
MM Levy et al.
CRITICAL CARE MEDICINE (2003)
分享论文
